Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04772885
Recruitment Status : Recruiting
First Posted : February 26, 2021
Last Update Posted : June 16, 2021
Sponsor:
Information provided by (Responsible Party):
Kymera Therapeutics, Inc.

Brief Summary:
KT-474 is an oral heterobifunctional small molecule IRAK4 degrader being developed for the treatment of interleukin-1 receptor (IL-1R)/toll-like receptor (TLR)-driven immune-inflammatory diseases. This first-in-human (FIH) study will characterize the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of a single ascending dose and multiple ascending doses of KT-474 in healthy volunteers and patients with atopic dermatitis (AD) or hidradenitis suppurativa (HS). The effects of food on the absorption of KT-474 will also be evaluated in healthy volunteers.

Condition or disease Intervention/treatment Phase
Healthy Volunteer Atopic Dermatitis Hidradenitis Suppurativa Drug: KT-474/Placebo Drug: KT-474 Phase 1

Detailed Description:
This is a first-in-human (FIH), Phase 1 randomized, placebo-controlled, single and multiple ascending dose trial of KT-474 that will characterize the safety, PK and PD of orally administered KT-474 after a single dose (Part A) and after repeated dosing first in healthy adult volunteers (Part B) and then in patients with AD or HS (Part C). Initially, a dose range of KT-474 in single ascending dose (SAD) escalation cohorts will be explored in healthy subjects. Up to two single dose cohorts of healthy subjects is also planned to understand food effects (FE) on the PK of KT-474. Enrollment of healthy subjects into 2-week multiple ascending dose (MAD) escalation cohorts will be initiated once sufficient safety and PK data from multiple SAD cohorts are available to inform the safe starting dose for the 2-week MAD portion of the study. After the MAD portion in healthy subjects is completed, the safety, PK, and PD of a dose of KT-474 that was found to be safe in healthy subjects when administered for 2 weeks will then be evaluated in AD or HS subjects for two weeks of dosing.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 124 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Single ascending dose escalation and multiple ascending dose escalation study followed by an evaluation of food effects on absorption
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: randomized double blind
Primary Purpose: Treatment
Official Title: A Phase 1 Randomized, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)
Actual Study Start Date : February 23, 2021
Estimated Primary Completion Date : February 1, 2022
Estimated Study Completion Date : February 1, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Single ascending dose cohorts in healthy subjects
Healthy volunteer subject cohorts randomized 6:2 receiving a single dose of KT-474 or placebo. The first cohort will receive 25 mg of KT-474 or placebo. Dose escalation will occur if KT-474 or placebo is tolerated.
Drug: KT-474/Placebo
KT-474 or matching placebo oral tablet(s)

Experimental: Multiple ascending dose cohorts in healthy subjects
Healthy volunteer subject cohorts randomized 9:3 to receive KT-474 or placebo for 14 days continuous dosing. The first cohort will receive a dose of KT-474 or placebo determined to be safe based on data generated in the SAD portion.
Drug: KT-474/Placebo
KT-474 or matching placebo oral tablet(s)

Experimental: Food Effect Cohort in healthy subjects
Healthy Volunteer SAD subject cohorts (up to 2) will return for a second treatment period and will receive the same treatment which was originally allocated, but in the fed state.
Drug: KT-474/Placebo
KT-474 or matching placebo oral tablet(s)

Experimental: Multiple dose cohort in HS and AD patients
A single cohort of up to 20 patients with AD or HS to receive a dose of KT-474 determined to be safe based on data generated in the healthy volunteer MAD portion, dosed daily X 14 days.
Drug: KT-474
KT-474 oral tablet(s)




Primary Outcome Measures :
  1. Incidence and severity of treatment emergent Adverse Events [ Time Frame: up to 28 days ]
  2. Incidence and frequency of use of concomitant medication [ Time Frame: up to 28 days ]

Secondary Outcome Measures :
  1. Area under the curve plasma concentration from time zero to infinity [AUC(0-∞)] (single dose only) [ Time Frame: up to 28 days ]
  2. Area under the curve plasma concentration from time zero to last measurable concentration [AUC(0-last)] [ Time Frame: up to 28 days ]
  3. Area under the plasma concentration-time curve during a dosing interval [AUC(0-tau)] [ Time Frame: up to 28 days ]
  4. Maximum observed plasma concentration (Cmax) [ Time Frame: up to 28 days ]
  5. Time to maximum observed plasma concentration (Tmax) [ Time Frame: up to 28 days ]
  6. Apparent clearance (CL/F) [ Time Frame: up to 28 days ]
  7. Apparent volume of distribution (Vz/F) [ Time Frame: up to 28 days ]
  8. Terminal elimination half-life (t1/2) [ Time Frame: up to 28 days ]
  9. Mean residence time (MRT) [ Time Frame: up to 28 days ]
  10. Renal clearance (CLR) [ Time Frame: up to 28 days ]

Other Outcome Measures:
  1. IRAK4 levels in peripheral blood mononuclear cells [ Time Frame: up to 28 days ]
  2. IRAK4 levels in skin [ Time Frame: up to 28 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Healthy Volunteer (Parts A and B) Inclusion Criteria:

  1. Male and female subjects, including female subjects of child bearing potential, between the ages of 18 and 55 with a weight at least 50 kg and a body mass index (BMI) between 18.0 and 30.0 kg/m2.
  2. Subjects confirmed as negative in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection test at Screening and on Day -2.
  3. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
  4. Agreement and ability to comply with all contraception requirements if applicable.
  5. All subjects must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Healthy Volunteer (Parts A and B) Exclusion Criteria:

  1. Evidence or history of a clinically significant medical condition or other condition that might significantly interfere with the absorption, distribution, metabolism, or excretion of study drug, or place the subject at an unacceptable risk as a participant in this study.
  2. Healthy volunteers who have a clinically relevant history or presence of respiratory, GI, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, or connective tissue diseases or disorders.
  3. Healthy volunteers who have any known factor, condition, or disease that might interfere with treatment compliance, study conduct or interpretation of the results such as drug or alcohol dependence or psychiatric disease.
  4. Female Healthy volunteers who are pregnant, trying to become pregnant or lactating or breastfeeding.
  5. Healthy volunteers who have participated in any investigational drug or device clinical study within 3 months prior to first dosing on this study.
  6. Healthy volunteers who have previously participated in a study with an investigational product or device involving the dosing of a biological targeted at any immune pathway within 1 year prior to Screening.

AD or HS Patient (Part C) Inclusion Criteria:

  1. Male or female patients aged 18 years to 55 years (inclusive) at the time of Screening, and in generally good health, except for AD or HS, and has a BMI of 17.5 to 35.0 kg/m2; and a total body weight >50 kg (110 lb).
  2. Diagnosis of AD or HS for at least 6 months.
  3. Patients with AD: having at least 25% treatable percentage body surface area at Screening or on Admission (excluding the scalp and designated venous access areas).
  4. Willingness and ability to comply with all contraception requirements as applicable based on reproductive status.
  5. Has an Investigator's static global assessment score of moderate (3) or severe (4) at Screening or on Day -1.
  6. Has adequate venous access with venous access sites having AD-unaffected, non-infected skin to permit repeated PK sampling.
  7. Female patients must have a negative result for the serum pregnancy test at the Screening Visit and at the follow-up visit.
  8. Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study.
  9. Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

AD or HS Patient (Parts C) Exclusion Criteria:

  1. Has any clinically significant medical disorder, condition, disease (including active or potentially recurrent dermatological conditions other than AD or HS), significant physical examination or laboratory findings that may interfere with study objectives, in the Investigator's opinion (eg, conditions or findings that may expose a patient to unacceptable risk by study participation, confound the evaluation of treatment response or adverse events, or otherwise interfere with a patient's ability to complete the study).
  2. Has unstable AD or HS or a consistent requirement for strong to strongest potency topical corticosteroids to manage AD or HS signs and symptoms.
  3. Has an active systemic or localized infection, including known actively-infected AD or HS.
  4. Treatment with an investigational product within 30 days or 5 half-lives preceding the first dose of investigational product (whichever is longer).
  5. Use of prescription or nonprescription drugs including topical corticosteroids, vitaminic and dietary supplements within 14 days or 5 half-lives (whichever is longer) prior to the first dose of investigational product.
  6. Blood donation (excluding plasma donations and platelet donations) of approximately ≥400 mL within 3 months or ≥200 mL within a month prior to dosing.
  7. History of sensitivity to heparin or heparin-induced thrombocytopenia.
  8. Unwilling or unable to comply with the protocol procedures and/or assessments.
  9. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04772885


Contacts
Layout table for location contacts
Contact: Kymera Clinical Trials 857-285-5300 clinicaltrials@kymeratx.com

Locations
Layout table for location information
United States, Florida
Research Centers of America Recruiting
Hollywood, Florida, United States, 22024
Contact: Andrea Janse       andrea.janse@rcatrials.com   
United States, New Jersey
TKL Research Recruiting
Fair Lawn, New Jersey, United States, 07410
Contact: Philip LaStella, MD    201-587-0500      
Sponsors and Collaborators
Kymera Therapeutics, Inc.
Investigators
Layout table for investigator information
Study Director: Ashwin Gollerkeri, MD Kymera Therapeutics, Inc.
Layout table for additonal information
Responsible Party: Kymera Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT04772885    
Other Study ID Numbers: KT474-HV-101
First Posted: February 26, 2021    Key Record Dates
Last Update Posted: June 16, 2021
Last Verified: February 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Kymera Therapeutics, Inc.:
Atopic Dermatitis
Hidradenitis Suppurativa
Immune-inflammatory diseases
Additional relevant MeSH terms:
Layout table for MeSH terms
Hidradenitis Suppurativa
Dermatitis, Atopic
Dermatitis
Eczema
Hidradenitis
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Sweat Gland Diseases
Skin Diseases, Bacterial
Bacterial Infections
Bacterial Infections and Mycoses
Infections
Skin Diseases, Infectious
Suppuration